Literature DB >> 16353917

On some "disadvantages" of the population approach.

Jerry R Nedelman1.   

Abstract

In a seminal article on population pharmacokinetic modeling, researchers demonstrated how means and variances of pharmacokinetic parameters for a patient population could be inferred from sparse data collected under conditions of routine patient care. But they also identified 4 potential concerns about their methodology: unobserved confounding variables may bias the inferences; conditions under which data are collected may lead to inaccuracies of reporting or recording; correlations among important predictor variables may reduce statistical efficiency; and costs cannot be controlled by principles of study design. Experiences are reviewed that relate to these potential disadvantages. A method is presented for diagnosing the possible presence of confounding. A model is constructed and applied that captures the influences of data inaccuracies. An example of selecting from among correlated covariates is summarized. Finally, a methodology for optimal study design is reviewed and applied to an example.

Entities:  

Mesh:

Year:  2005        PMID: 16353917      PMCID: PMC2750975          DOI: 10.1208/aapsj070238

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  21 in total

1.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.

Authors:  S Retout; S Duffull; F Mentré
Journal:  Comput Methods Programs Biomed       Date:  2001-05       Impact factor: 5.428

Review 2.  Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches.

Authors:  R J Little; D B Rubin
Journal:  Annu Rev Public Health       Date:  2000       Impact factor: 21.981

3.  Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test.

Authors:  K G Kowalski; M M Hutmacher
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

4.  Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics.

Authors:  Sylvie Retout; France Mentré
Journal:  J Biopharm Stat       Date:  2003-05       Impact factor: 1.051

5.  Population one-compartment pharmacokinetic analysis with missing dosage data.

Authors:  Dolors Soy; Stuart L Beal; Lewis B Sheiner
Journal:  Clin Pharmacol Ther       Date:  2004-11       Impact factor: 6.875

6.  Automated covariate model building within NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

7.  Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance.

Authors:  J Lu; J M Gries; D Verotta; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-08       Impact factor: 2.745

8.  Prospective evaluation of a D-optimal designed population pharmacokinetic study.

Authors:  Bruce Green; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-04       Impact factor: 2.745

9.  Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies.

Authors:  Bernard Vrijens; Els Goetghebeur
Journal:  Stat Med       Date:  2004-02-28       Impact factor: 2.373

10.  Estimation of population pharmacokinetic parameters in the presence of non-compliance.

Authors:  Song Mu; Thomas M Ludden
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-02       Impact factor: 2.745

View more
  3 in total

1.  Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age.

Authors:  James H Fischer; Gloria E Sarto; Mitra Habibi; Sarah J Kilpatrick; Ruth E Tuomala; Janice M Shier; Lori Wollett; Patricia A Fischer; Kinnari S Khorana; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

2.  Approaches to handling missing or "problematic" pharmacology data: Pharmacokinetics.

Authors:  Donald J Irby; Mustafa E Ibrahim; Anees M Dauki; Mohamed A Badawi; Sílvia M Illamola; Mingqing Chen; Yuhuan Wang; Xiaoxi Liu; Mitch A Phelps; Diane R Mould
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-04

3.  A Systematic Evaluation of Effect of Adherence Patterns on the Sample Size and Power of a Clinical Study.

Authors:  Surulivelrajan Mallayasamy; Ayyappa Chaturvedula; Terrence Blaschke; Michael J Fossler
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-10-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.